Sidley has announced that Lila Hope and Jennifer Raab have joined Sidley’s office in Palo Alto as partners in the firm’s Technology and Life Sciences Transactions […]
Sidley Adds Life Sciences Transactions Partners Lila Hope and Jennifer Raab in Palo Alto
BioAge Labs’ $238 Million Upsized Initial Public Offering
Fenwick & West represented BioAge Labs, Inc. in the offering, and Cooley represented the underwriters. BioAge Labs, Inc. (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic...
SystImmune’s Licensing and Collaboration Agreement with Bristol Myers Squibb
Cooley advised SystImmune on the transaction. SystImmune announced its exclusive license and collaboration agreement with Bristol Myers Squibb (NYSE: BMY) for SystImmune’s BL-B01D1. Under the terms of...
Neumora Therapeutics’ $250.1 Million Initial Public Offering
Latham & Watkins advised Neumora, and Cooley advised the underwriters. Neumora Therapeutics, Inc. announced the pricing of its initial public offering of 14,710,000 shares of its common...
Turnstone Biologics Corp.’s $80 Million Initial Public Offering
Cooley represented Turnstone, and Latham & Watkins represented the underwriters in the IPO. Turnstone Biologics Corp. (Nasdaq: TSBX) announced the pricing of its upsized initial public...
Seven and Eight Biopharmaceuticals’ License Agreement with Eikon Therapeutics
Cooley advised Seven and Eight Biopharmaceuticals on the deal. Seven and Eight Biopharmaceuticals Inc. announced that it has signed an exclusive licensing agreement with Eikon Therapeutics....
Impact Therapeutics’ Global Partnership with Eikon Therapeutics
Cooley advised Impact Therapeutics on the deal. Impact Therapeutics and Eikon Therapeutics announced that the companies have entered into a global license and collaboration agreement for PARP1 selective inhibitors...
Zai Lab’s License Agreement with MediLink Therapeutics
Cooley advised Zai Lab on the deal. Zai Lab, a research-based commercial-stage biopharmaceutical company, announced its strategic partnership and exclusive worldwide license agreement with MediLink Therapeutics, as...
Roche’s Acquisition of Zion Pharma’s Lead Program Title
Cooley advised Zion Pharma Limited on the deal. Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, announced the acquisition of its...
RTW’s $125 Million Investment in Milestone Pharmaceuticals
Gibson Dunn acted as legal advisor to RTW, and Cooley acted as legal advisor to Milestone. Milestone Pharmaceuticals Inc. announced that it has entered into a...
Carlyle and Abingworth’s $170 Million Non-dilutive Financing of Opthea
Goodwin Procter and Debevoise & Plimpton advised Carlyle on the deal, while Cooley and Gilbert+Tobin advised Opthea. Global investment firm Carlyle and its life sciences franchise...
Lulu’s Fashion Lounge Holdings’ $92 Million Initial Public Offering
Latham & Watkins represented Lulu’s in the offering while Cooley advised the underwriters. Lulu’s Fashion Lounge Holdings, Inc., a customer driven, digitally native women’s fashion brand, has...